Travere Therapeutics (TVTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Travere Therapeutics Revenue Highlights

Latest Revenue (Y)

$145.24M

Latest Revenue (Q)

$62.90M

Main Segment (Y)

License

Travere Therapeutics Revenue by Period

Travere Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$145.24M	-31.50%
2022-12-31	$212.02M	-6.80%
2021-12-31	$227.49M	14.71%
2020-12-31	$198.32M	13.11%
2019-12-31	$175.34M	6.75%
2018-12-31	$164.25M	6.01%
2017-12-31	$154.94M	15.98%
2016-12-31	$133.59M	33.74%
2015-12-31	$99.89M	254.19%
2014-12-31	$28.20M	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2012-02-29	-	100.00%
2011-02-28	-	100.00%
2010-02-28	-	100.00%
2009-02-28	-	-

Travere Therapeutics generated $145.24M in revenue during NA 2023, up -31.50% compared to the previous quarter, and up 88.43% compared to the same period a year ago.

Travere Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$62.90M	16.23%
2024-06-30	$54.12M	30.80%
2024-03-31	$41.37M	-8.18%
2023-12-31	$45.06M	21.47%
2023-09-30	$37.09M	-37.86%
2023-06-30	$59.70M	4.74%
2023-03-31	$56.99M	2.01%
2022-12-31	$55.87M	4.43%
2022-09-30	$53.50M	-1.24%
2022-06-30	$54.17M	11.71%
2022-03-31	$48.49M	-15.31%
2021-12-31	$57.25M	-16.08%
2021-09-30	$68.22M	24.90%
2021-06-30	$54.62M	15.21%
2021-03-31	$47.41M	-7.01%
2020-12-31	$50.98M	-0.31%
2020-09-30	$51.14M	5.59%
2020-06-30	$48.43M	1.38%
2020-03-31	$47.77M	2.32%
2019-12-31	$46.69M	5.21%
2019-09-30	$44.37M	-0.75%
2019-06-30	$44.71M	12.98%
2019-03-31	$39.57M	-9.60%
2018-12-31	$43.77M	7.53%
2018-09-30	$40.71M	-1.53%
2018-06-30	$41.34M	7.56%
2018-03-31	$38.43M	-8.88%
2017-12-31	$42.18M	4.55%
2017-09-30	$40.34M	3.97%
2017-06-30	$38.80M	15.41%
2017-03-31	$33.62M	-9.93%
2016-12-31	$37.33M	9.96%
2016-09-30	$33.95M	1.90%
2016-06-30	$33.31M	14.83%
2016-03-31	$29.01M	-4.73%
2015-12-31	$30.45M	8.72%
2015-09-30	$28.00M	16.36%
2015-06-30	$24.07M	38.55%
2015-03-31	$17.37M	23.34%
2014-12-31	$14.08M	68.71%
2014-09-30	$8.35M	45.40%
2014-06-30	$5.74M	20479.69%
2014-03-31	$27.90K	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-11-30	-	100.00%
2012-08-31	-	100.00%
2012-05-31	-	100.00%
2012-02-29	-	100.00%
2011-11-30	-	100.00%
2011-08-31	-	100.00%
2011-05-31	-	100.00%
2011-02-28	-	100.00%
2010-11-30	-	100.00%
2010-08-31	-	100.00%
2010-05-31	-	-

Travere Therapeutics generated $62.90M in revenue during Q3 2024, up 16.23% compared to the previous quarter, and up 105.36% compared to the same period a year ago.

Travere Therapeutics Revenue Breakdown

Travere Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
License	$17.70M	-	-	-	-
Active Pharmaceutical Ingredient	$3.30M	-	-	-	-
Bile Acid Products	-	$102.56M	$95.65M	$89.44M	$79.70M
Tiopronin Products	-	$97.97M	$115.12M	$108.88M	-
Product	-	$200.53M	$210.78M	-	-
Thiola License	-	-	-	-	$95.64M

Travere Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (84.29%), and Active Pharmaceutical Ingredient (15.71%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Product	$61.00M	$52.18M	$39.98M	$57.01M	$50.28M	$52.34M	$50.79M	$50.95M	$46.44M	$54.58M	$54.17M	-	-	-	-	-	-	-	-	-
License	$1.90M	$1.94M	$1.39M	$14.54M	$3.16M	$2.67M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	-	-	-	$3.30M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bile Acid Products	-	-	-	-	-	$27.50M	$26.11M	$26.53M	$25.42M	$25.53M	$25.07M	$24.35M	$24.97M	$21.96M	$22.67M	$22.91M	$21.57M	$22.28M	$20.44M	-
Tiopronin Products	-	-	-	-	-	$26.05M	$21.17M	$25.82M	$25.37M	$25.42M	$21.37M	$29.82M	$29.64M	$25.44M	$28.31M	$28.23M	$26.86M	$25.49M	-	-

Travere Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (96.98%), and License (3.02%).

Travere Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

Country	Mar 22
FRANCE	$8.00M

Travere Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 22: FRANCE (100.00%).

Travere Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
LEGN	Legend Biotech	$285.14M	$93.99M
TVTX	Travere Therapeutics	$145.24M	$62.90M
PTGX	Protagonist Therapeutics	$60.00M	$4.67M
IDYA	IDEAYA Biosciences	$23.39M	-
ANAB	AnaptysBio	$17.16M	$30.02M
MGTX	MeiraGTx	$14.02M	$10.91M
RVMD	Revolution Medicines	$11.58M	-
RNA	Avidity Biosciences	$9.56M	$2.04M
STOK	Stoke Therapeutics	$8.78M	$4.89M
CYTK	Cytokinetics	$7.53M	$463.00K
KROS	Keros Therapeutics	$151.00K	$37.00K
GPCR	Structure Therapeutics	-	-
PCVX	Vaxcyte	-	-
NUVL	Nuvalent	-	-
COGT	Cogent Biosciences	-	-
VTYX	Ventyx Biosciences	-	-
AKRO	Akero Therapeutics	-	-

TVTX Revenue FAQ

What is Travere Therapeutics’s yearly revenue?

Travere Therapeutics's yearly revenue for 2023 was $145.24M, representing a decrease of -31.50% compared to 2022. The company's yearly revenue for 2022 was $212.02M, representing a decrease of -6.80% compared to 2021. TVTX's yearly revenue for 2021 was $227.49M, representing an increase of 14.71% compared to 2020.

What is Travere Therapeutics’s quarterly revenue?

Travere Therapeutics's quarterly revenue for Q3 2024 was $62.9M, a 16.23% increase from the previous quarter (Q2 2024), and a 69.56% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $54.12M, a 30.80% increase from the previous quarter (Q1 2024), and a -9.35% decrease year-over-year (Q2 2023). TVTX's quarterly revenue for Q1 2024 was $41.37M, a -8.18% decrease from the previous quarter (Q4 2023), and a -27.41% decrease year-over-year (Q1 2023).

What is Travere Therapeutics’s revenue growth rate?

Travere Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -36.16%, and for the last 5 years (2019-2023) was -17.17%.

What are Travere Therapeutics’s revenue streams?

Travere Therapeutics's revenue streams in c 23 are License, and Active Pharmaceutical Ingredient. License generated $17.7M in revenue, accounting 84.29% of the company's total revenue Active Pharmaceutical Ingredient generated $3.3M in revenue, accounting 15.71% of the company's total revenue

What is Travere Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Travere Therapeutics was License. This segment made a revenue of $17.7M, representing 84.29% of the company's total revenue.